The role of lncRNAs in regulation of DKD and diabetes-related cancer

Yawei Cheng1,2*, Xiaowen Wu1, Yujie Xia3, Wenjun Liu4 and Peter Wang4*

1Department of Disease Prevention, Hainan Province Hospital of Traditional Chinese Medicine, Haikou, China, 2Hainan Clinical Research Center for Preventive Treatment of Diseases, Haikou, China, 3Department of Food Science and Technology Centers, National University of Singapore (Suzhou) Research Institute, Suzhou, China, 4Department of Research and Development, Zhejiang Zhongwei Medical Research Center, Hangzhou, China

Diabetes mellitus often results in several complications, such as diabetic kidney disease (DKD) and end-stage renal diseases (ESRDS). Cancer patients often have the dysregulated glucose metabolism. Abnormal glucose metabolism can enhance the tumor malignant progression. Recently, lncRNAs have been reported to regulate the key proteins and signaling pathways in DKD development and progression and in cancer patients with diabetes. In this review article, we elaborate the evidence to support the function of lncRNAs in development of DKD and diabetes-associated cancer. Moreover, we envisage that lncRNAs could be diagnosis and prognosis biomarkers for DKD and cancer patients with diabetes. Furthermore, we delineated that targeting lncRNAs might be an alternative approach for treating DKD and cancer with dysregulated glucose metabolism.

KEYWORDS
lncRNAs, cancer, diabetes, DKD, miRNAs, treatment

Abbreviations: α-SMA, alpha smooth muscle actin; α1-MG, α1-microglobulin; APEX2, ascorbate peroxidase; β2-MG, β2-microglobulin; BSA, bovine serum albumin; CASC2, cancer susceptibility candidate 2; ChREBP, carbohydrate response element binding protein; CTGF, connective tissue growth factor; DRAIR, diabetes regulated anti-inflammatory IncRNA; DKD, diabetic kidney disease; HbA1c, glycosylated hemoglobin; HDAC1, histone deacetylase 1; HKDC1, hexokinase domain-containing 1; HOTAIR, HOX antisense intergenic RNA; IncRNAs, long noncoding RNAs; MEG3, maternally expressed gene 3; MLX, MAX dimerization protein; MXD1, MAX dimerization protein 1; NEAT, nuclear-enriched abundant transcript; PBMC, peripheral blood mononuclear cells; PGC-1α, peroxisome proliferator-activated receptor γ coactivator α; SOD, superoxide dismutase; TGF-β1, transforming growth factor-β1; TME, tumor microenvironment; TUG1, taurine upregulated gene 1.
Introduction

Noncoding RNAs have been known to play an essential role in development of many diseases (1, 2). Noncoding RNAs include short non-coding RNAs, such as microRNAs (miRNAs), small interfering RNA (siRNAs), piwi-interacting RNA (piRNAs), transfer RNA (tRNAs), small nuclear RNA (snRNAs) and small nucleolar RNA (snoRNAs), and long non-coding RNAs (lncRNAs), which is based on their length (3). LncRNAs often have more than 200 nucleotides and cancer serve as signal molecules, decoy molecules, guide molecules, and scaffold molecules to perform their functions via regulation of gene expression at epigenetic, transcriptional and post-transcriptional levels (4, 5). Accumulated evidence has dissected that lncRNAs participate in cellular biological processes via regulation of protein degradation and governing gene transcription as well as controlling protein coding sections (6–8). Dysregulated lncRNAs have been reported to participate in numerous diseases, including cancer, inflammatory bowel disease, cardiovascular disease, neurological disorders and diabetes (9–14).

Diabetes mellitus (DM) has become a major health problem in the world, which often results in several complications, such as diabetic kidney disease (DKD) (15). DKD is often known as diabetic nephropathy. DM has three types: type 1 diabetes, type 2 diabetes and gestational diabetes (GDM). Type 1 diabetes is insulin-dependent and often appears during childhood and adolescence. Type 2 diabetes often appears in older adults due to that pancreas does not make enough insulin or cells respond poorly to insulin. GDM often happens during the pregnancy after insulin secretion is not enough. DKD is one of causes to develop end stage kidney disease (ESKD) and kidney failure (16). It has been known that chronic stimuli such as high glucose in the bloodstream can lead to pathological gene modulation and development of many diseases (1, 2). Noncoding RNAs have been known to play an essential role in development of many diseases (1, 2). Noncoding RNAs include short non-coding RNAs, such as microRNAs (miRNAs), small interfering RNA (siRNAs), piwi-interacting RNA (piRNAs), transfer RNA (tRNAs), small nuclear RNA (snRNAs) and small nucleolar RNA (snoRNAs), and long non-coding RNAs (lncRNAs), which is based on their length (3). LncRNAs often have more than 200 nucleotides and cancer serve as signal molecules, decoy molecules, guide molecules, and scaffold molecules to perform their functions via regulation of gene expression at epigenetic, transcriptional and post-transcriptional levels (4, 5). Accumulated evidence has dissected that lncRNAs participate in cellular biological processes via regulation of protein degradation and governing gene transcription as well as controlling protein coding sections (6–8). Dysregulated lncRNAs have been reported to participate in numerous diseases, including cancer, inflammatory bowel disease, cardiovascular disease, neurological disorders and diabetes (9–14).

DKD in diabetic patients (17). EMT and endothelial-mesenchymal transition (EndMT) have been characterized to integrate into the fibrosis and DKD (18, 19). EMT is a process in which epithelial cells acquire mesenchymal characteristics after various stimulations. Similarly, EndMT is a process in which endothelial cells have the phenotype toward mesenchymal cells, which often appears in cardiovascular diseases. Cancer patients often have the dysregulated glucose metabolism. Abnormal glucose metabolism can enhance the tumor malignant progression (20).

Recently, noncoding RNAs, including lncRNAs, have been reported to regulate the key proteins and signaling pathways in DM and DKD development and progression as well as in cancer with diabetes (21–24). In this review article, we elaborate the evidence to support the function of lncRNAs in development of DKD and cancer patients with diabetes. Moreover, we envisage that lncRNAs could be diagnostic and prognosis biomarkers for DKD and diabetes-related cancers. Furthermore, we delineated that targeting lncRNAs might be an alternative approach for treating DKD and diabetes-associated cancer.

Role of lncRNAs in DKD

Emerging evidence has suggested that lncRNAs are useful for precision medicine in DKD (25–28). Zhang and colleagues used the integrate biological, computational, and statistical strategies to analyze the pathogenesis and progression of DKD through analysis of regulatory networks including miRNAs, lncRNAs and mRNAs (29). This study reported that 127 lncRNAs were changes in DKD, among which 26 were decreased and 101 were increased. In particular, this work identified that miR-223-3p might be a biomarker for prediction of DKD disease process (29).

LncRNA HOTAIR

Evidence showed that lncRNA HOTAIR is critically involved in DKD development (30). One group used several mouse models, such as podocyte-specific Hotair knockout mice, streptozotocin-induced diabetes in mice, and the db/db mouse model of type 2 diabetes. In these mouse models, glomerular HOTAIR was upregulated. Depletion of Hotair in podocytes did not affect structure, ultrastructure, function of kidneys (30). In mouse podocytes, high glucose treatment increased the expression of HOTAIR. Interestingly, silencing of HOTAIR did not affect the kidney damage in diabetic mice. Moreover, HOTAIR expression was linked to HOXC11 expression in human kidney tissues according to a bioinformatic assay (30). Notably, the serum level of HOTAIR was increased in type 2 DM patients (31). HOTAIR can be a useful biomarker in prediction of diabetic retinopathy and DKD in patients with type 2 DM. In addition, HOTAIR facilitated high glucose-mediated fibrosis and proliferation of mesangial cells via affecting miR-147a/ WNT2B axis in diabetic nephropathy (32). The role of HOTAIR in DKD needs to be ascribed to validate its function in the pathogenesis of DKD.

LncRNA GAS5

Wang et al. reported that lncRNA GAS5 promoted renal tubular epithelial fibrosis via sponging miR-96-5p (33). Renal fibrosis is often observed in DKD. Higher expression of lncRNA GAS5 was reported in renal proximal tubular cells after TGF-β1 treatment. The kidneys of high-fat diet (HFD)/streptozotocin (STZ) mice had the upregulation of lncRNA GAS5 (33). Silencing of lncRNA GAS5 reduced renal fibrosis via inhibition of miR-96-5p. Consistently, DKD mice had the lower expression of miR-96-5p, leading to upregulation of
fibronectin. Hence, depletion of lncRNA GAS5 could have antifibrosis via sponging miR-96-5p and regulating fibronectin. Zhang et al. found that lncRNA GAS5 attenuated TGF-β-mediated renal fibrosis by inhibition of collagen type 1 an fibronectin via targeting the Smad3/miR-142-5p axis (34). LncRNA GAS5 suppressed fibrosis and cell proliferation through attenuating miR-221 and upregulating SIRT1 expression in diabetic nephropathy (35). LncRNA GAS5 inhibited pyroptosis and oxidative stress in renal tubular cells after high glucose stimulation (36). LncRNA GAS5 alleviated fibrosis via inhibition of MMP9 by recruitment of EZH2 in diabetic nephropathy (37). Altogether, modulation of lncRNA GAS5 might be useful for preventing DKD.

LncRNA MALAT1

LncRNA MALAT1 has been identified to play key roles in DKD pathophysiology (38). One work assessed urinary albumin in 136 patients with type 2 DM and 25 normal people. This work found that urinary lncRNA MALAT1 was positively associated with urinary podocalyxin, synaptopodin, UACR (urinary albumin), NAG (N-acetyl-D-glucosaminidase), KIM-1 (kidney injury molecule 1), miR-21, miR-93, miR-29a (38). LncRNA MALAT1 was negatively associated with eGFR, miR-29a and miR-93. In addition, urinary lncRNA MIAT was positively linked to miR-29a, miR-93 and eGFR, while lncRNA MIAT was negatively associated with miR-21, miR-124, UACR, NAG and KIM-1 (38). In line with this report, the expression of LncRNA MALAT1 in PBMC was increased in type 2 DM and DKD (39). MALAT1 was associated with ACR, HbA1c, SOD, creatinine, α1-MG and β2-MG in type 2 DM and DKD patients. MALAT1 in combination with ACR, α1-MG and creatinine could be helpful for prediction of DKD in DM patients (39). MALAT1 enhanced diabetic nephropathy via suppression of miR-15b-5p and upregulation of TLR4 signaling (40).

MALAT1 activated LIN28 and Nox4/AMPK/mTOR pathway, resulting in promotion of renal tubular injury in diabetic nephropathy (41). Huang et al. reported that MALAT1 aggravated renal fibrosis via modulation of miR-2353-3p/IL6ST axis in diabetic nephropathy (42). One study showed that podocyte injury could be due to abnormal MALAT1 expression and subsequent dysregulated let-7f and KLF5 in diabetic nephropathy (43). MALAT1 was also reported to participate in high glucose-mediated HK-2 cell EMT via activation of Wnt/β-catenin pathway and injury (44). Consistently, MALAT1 was involved in high glucose-mediated podocyte injury in diabetic nephropathy via its interaction with β-catenin (45). MALAT1 aggravated high glucose-triggered EndMT and fibrosis through regulation of miR-145/ZEB2 axis (46). Additionally, MALAT1 participated in high glucose-mediated HK-2 cell injury via interplay with Foxo1 to affect SIRT expression (47).

LncRNA NEAT1

Evidence has suggested that lncRNA NEAT1 governed renal tubular EMT via regulation of the ERK1/2 signaling pathway in DKD (52). LncRNA NEAT1 was increased in BSA-treated HK2 cells and HFD/STZ-induced DKD mice. Depletion of NEAT1 suppressed the expression of the EMT-related markers, such as vimentin and a-SMA, and the renal fibrosis-associated markers, including TGF-β1 and CTGF (52). LncRNA NEAT1 regulated DKD progression via modulation of the ERK1/2 signaling pathway. Li et al. discovered that NEAT1 interacted with miR-129 to promote renal fibrosis via upregulation of collagen type 1 and promotion of EMT process (53). Additionally, urinary lncRNA NEAT1 was positively correlated with miR-21, miR-124, KIM-1, synaptopodin, and NAG in type 2 DM. Urinary lncRNA NEAT1 had a negative association with miR-29a, miR-93 and eGFR (38).

LncRNA NEAT1 activated Akt/mTOR pathway and accelerated cell fibrosis and proliferation in diabetic nephropathy (54). LncRNA NEAT1 enhanced EMT and accumulation of extracellular matrix in diabetic nephropathy via sponging miR-27b-3p and ZEB1 (55). Ablation of LncRNA NEAT1 attenuated proliferation, fibrosis and inflammation of mouse mesangial cells in diabetic nephropathy (56). In addition, LncRNA NEAT1 accelerated diabetic nephropathy occurrence and progression via suppression of miR-23c (57). LncRNA NEAT1 affected pyroptosis via targeting the miR-34c and NLRP3 in diabetic nephropathy (58). One group showed that LncRNA NEAT1 accelerated high glucose-triggered hypertrophy in mesangial cells through modulating miR-222-3p and CDKN1B (59). Yang et al. found that LncRNA NEAT1 enhanced tubular epithelial cell damage in kidney through regulation of mitophagy by targeting miR-150-5p and...
DRP1 in diabetic nephropathy (60). Moreover, lncRNA NEAT1 promoted fibrosis, inflammation, proliferation and oxidative stress by modification of the miR-423/5p and GLI1PR2 pathway in diabetic nephropathy (61). Hence, lncRNA NEAT1 might be a promising therapeutic target for the treatment of DKD.

**LncRNA TUG1**

LncRNA TUG1 has been identified to play a crucial role in DKD progression (62). One study revealed that ChREBP controlled lncRNA TUG1 transcription when glucose levels were increased in podocytes (62). Besides ChREBP, other coregulators, such as MXD1, MLX and HDAC1, were increased at the TUG1 promoter in response to high glucose exposures. This work suggested that ChREBP coordinated increased at the TUG1 promoter in response to high glucose exposures. Coregulators, such as MXD1, MLX and HDAC1, were increased at the TUG1 promoter in response to high glucose exposures.

Moreover, lncRNA TUG1 interacted with miR-141-3p/β-catenin (65). Another work also demonstrated that knockdown of lncRNA TUG1 retarded the EMT of renal tubular epithelial cells via targeting miR-141-3p/β-catenin (65). Urinary lncRNA TUG1 was positively associated with miR-29a, miR-93 and eGFR in type 2 DM, while lncRNA TUG1 had a negative association with miR-21, miR-124, podocalyxin, NAG and synaptopodin (38).

LncRNA TUG1 participated in regulation of podocyte apoptosis via modulation of TRAF5 pathway in diabetic nephropathy rats (68). LncRNA TUG1 influenced podocyte apoptosis via promotion of endoplasmic reticulum stress in diabetic nephropathy progression (69). Additionally, lncRNA TUG1 repressed the PI3K/AKT pathway and suppressed the fibrosis and proliferation in mesangial cells in diabetic nephropathy (70). LncRNA TUG1 inhibited the expression of miR-21 and enhanced the TIMP3 expression, leading to ameliorating diabetic nephropathy (71). LncRNA TUG1 repressed the PUL1/RTN1 pathway and improved diabetic nephropathy (72). Notably, lncRNA TUG1 affected high glucose-stimulated renal epithelial cell injury via regulation of endoplasmic reticulum stress by targeting miR-29c-3p and SIRT1 in diabetic nephropathy (73).

**LncRNA MEG3**

LncRNA MEG3 has been revealed to regulate glucose metabolisms in diabetic mice (74). STZ-mediated diabetic mice had an increased expression of lncRNA MEG3, which was associated with the podocyte numbers. Mice with knockdown of MEG3 in podocyte had improved renal physiological and histopathological features (74). These mice also had a reduced mitochondrial translocation of Drp1 and a decreased podocyte damage (74). Overexpression of lncRNA MEG3 in podocyte led to podocyte injury and enhanced mitochondria damage and upregulated expression and phosphorylation of Drp1 (74). LncRNA MEG3 increased fibrosis and inflammation through regulating miR-181a, Egr-1 and TLR4 in diabetic nephropathy (75). Moreover, lncRNA MEG3 sponged miR-145 and impacted the development of diabetic nephropathy (76). Strikingly, lncRNA MEG3 inactivated the Wnt/β-catenin pathway and reduced podocyte injury in diabetic nephropathy (77). Therefore, MEG3 plays an essential role in diabetic mice and DKD.

**LncRNA KCNQ1OT1**

Downregulation of KCNQ1OT1 attenuated oxidative stress and inflammation and reduced pyroptosis in renal tubular epithelial cells after high glucose stimulations through regulation of miR-506-3p (78). One study showed that KCNQ1OT1 participated in governing fibrosis, apoptosis and proliferation via regulation of miR-18b-5p and SORBS2 and NF-kB in diabetic nephropathy (79). Another study revealed that KCNQ1OT1 sponged miR-18b and increased the expression of HMG2 and led to controlling high glucose-triggered oxidative stress, proliferation and extracellular matrix promotion in mesangial cells (80). In addition, KCNQ1OT1 was reported to accelerate diabetic nephropathy development via modulating miR-93-5p/ROCK2 axis (81). Xu et al. dissected that KCNQ1OT1 governed cell oxidative stress, proliferation, inflammation and extracellular matrix enhancement through miR-147a/SOX6 pathway in diabetic nephropathy (82). Recently, KCNQ1OT1 expression in diabetic nephropathy was increased and associated with activation of MEK/ERK pathway in diabetic nephropathy (83). LncRNA KCNQ1OT1 participates in DKD development and progression.

**LINC00472**

Wang et al. used the data from Gene Expression Omnibus (GEO) database to explore the differentially expressed profiles
between DKD patients and the normal patients. This study found that among 252 lncRNAs, 14 lncRNAs were differentially expressed. LINC00472 was identified to be differentially expressed in DKD patients, suggesting that LINC00472 could act as the diagnostic biomarkers for DKD patients (84). It is required to explore the detailed role of LINC00472 in DKD.

LncRNA NONMMUG023520.2 and NONMMUG032975.2

Smad3 has been reported to enhance the development of type 2 DM and involve in DKD pathogenesis (85–87). One group discovered the Smad3-associated genes via analysis of whole transcriptome profile in three types of transgenic mouse models, including Smad3 WT-db/db, Smad3 KO-db/db, Smad3+/- db/db mice (88). Two lncRNAs, NONMMUG023520.2 and NONMMUG032975.2, were further validated to be linked to the pathogenesis of diabetic nephropathy. Moreover, Upk1b, Psca and Gdf15 were validated to be correlated with diabetic nephropathy (89). Consistently, lncRNA ENSG00000254693 was upregulated in human podocytes after high glucose exposures. Depletion of lncRNA 254693 attenuated apoptosis, inflammation, and podocyte injury that were induced by high glucose (89). Furthermore, lncRNA 254693 was found to combine with HuR, and depletion of lncRNA 254693 reduced HuR levels. Interestingly, silencing of HuR reduced the expression and stability of lncRNA 254693 and alleviated podocyte injury, apoptosis and inflammation (89). Therefore, lncRNA 254693 might be a predicted factor for DKD treatment.

LncRNA 254693

Increased evidence has revealed that lncRNA ENSG00000254693 participated in DKD development (89). One research used RNA sequencing data and observed numerous differentially expressed lncRNAs in renal specimens of DKD. Among these dysregulated lncRNAs, lncRNA ENSG00000254693 was drastically changed. Moreover, DKD patients had higher expression of lncRNA ENSG00000254693 (89). Consistently, lncRNA ENSG00000254693 was upregulated in human podocytes after high glucose exposures. Depletion of lncRNA 254693 attenuated apoptosis, inflammation, and podocyte injury that were induced by high glucose (89). Furthermore, lncRNA 254693 was found to combine with HuR, and depletion of lncRNA 254693 reduced HuR levels. Interestingly, silencing of HuR reduced the expression and stability of lncRNA 254693 and alleviated podocyte injury, apoptosis and inflammation (89). Therefore, lncRNA 254693 might be a predicted factor for DKD treatment.

Other lncRNAs in DM and DKD

LncRNA CASC2 expression in renal samples and serum was identified to be downregulated in type 2 DM patients with chronic renal failure (90). Low serum level of CASC2 was associated with higher incidence of kidney failure, indicating that serum lncRNA CASC2 could be a biomarker for prediction of the occurrence of kidney failure in type 2 DM patients (90). By RT-PCR analysis in 77 type 2 DM patients, 60 diabetic nephropathy and 60 healthy people, one group found that lncRNA PANDAR in the serum was upregulated compared with healthy people (91). PANDAR expression was linked to the level of proteinuria and glomerular filtration rate. PANDAR might serve as a biomarker for judgement of DKD prognosis (91). Yang et al. reported the differential expression profiles of circulating lncRNAs in DM and DKD patients. Compared with healthy persons, 245 lncRNAs were increased, while 680 lncRNAs were decreased in the serum of DM patients. Compared with diabetes patients, 45 and 813 lncRNAs were increased and decreased in the serum of DKD patients, respectively (92). LncRNA ARAP1-AS1 expression was elevated during DM and DKD progression, while lncRNA ARAP1-AS2 was decreased in DM and DKD progression (92). Hence, circulating lncRNA ARAP1-AS1 and ARAP1-AS2 might predict the progression of DM and DKD.

Another group identified that lncRNA KCNQ1OT1 was abnormally elevated in PBMCs of diabetic nephropathy, which was correlated with the activation of MEK/ERK pathway (83). LncRNA CASC2 modulated cell proliferation, oxidative stress and extracellular matrix promotion in human mesangial cells upon high glucose treatment through regulation of miR-133b and FOXP1 expressions (93). LncRNA CASC2 mitigated diabetic nephropathy development via sponging miR-144 and regulating SOCS2 expression (94). LncRNA CASC2 ablated cell inflammation, proliferation and fibrosis in glomerular mesangial cells upon high glucose exposures via targeting miR-135a-5p/TIMP3 pathway and JNK pathway (95).

LncRNAs regulate glucose metabolism in cancer

Competing endogenous RNAs (ceRNA) can compete for shared miRNAs to modulate the expression of other RNA transcripts. A ceRNA network profile has identified the several lncRNAs for classifying diabetic pancreatic cancer form non-diabetic pancreatic cancer, including HOTAIR, CECR7, UCA1, suggesting that lncRNAs are important predictors for diabetic pancreatic cancer (96). In the following paragraphs, we will discuss the association between lncRNAs and glucose metabolisms in human cancer (Figure 1).
**LncRNAs regulate glucose metabolism in cancer**

Evidence has dissected that lncRNA-associated genetic variants are shared between cancers and type 2 DM in human (97). LncRNA DRAIR has been known to involve in the development of type 2 DM (98). One study showed that the expression of lncRNA DRAIR was remarkably elevated in triple-negative breast cancer (TNBC) samples and plasma (99). High expression of DRAIR in plasma was associated with chemoresistance after therapy and tumor recurrence in TNBC patients. *In vitro* experiments showed that overexpression of DRAIR enhanced proliferation and viability of TNBC cells after doxorubicin treatment (99).

Accumulated evidence dissected that lncRNA HOXC-AS2 participated in the progression in high glucose-related endometrial cancer (EC) (100). EC patients with diabetes had the increased expression of HKDC1 compared with EC patients with normal glucose. HKDC1 governed pyroptosis, a highly inflammatory response of regulated cell death, via regulation of ROS and cytokine release in EC cells after high glucose stimulation (100). Moreover, miR-876-5p can inhibit the expression of HKDC1 in high glucose-related EC. LncRNA HOXC-AS2 was dissected to suppress the miR-876-5p/HKDC1 axis in high glucose-associated EC (100). HKDC1 affected the formation of TME via promotion of glycolysis, leading to accelerating EC progression. This work provided the new therapeutic strategy for EC patients with diabetes by targeting lncRNA HOXC-AS2 (100). LncRNA SNHG10

![Figure 1](https://frontiersin.org)  
*The role of lncRNAs in regulation of glucose metabolism in human cancers. EC, endometrial cancer; OS, osteosarcoma; HCC, hepatocellular carcinoma; CRC, colorectal cancer; GC, gastric cancer; NSCLC, non-small cell lung cancer.*
enhanced glucose uptake and increased proliferation of osteosarcoma cells via promotion of miR-218 methylation (101). LncRNA MALAT1 facilitated glycolysis and tumor metastasis via blocking miR-485-3p and upregulating c-MET and Akt3/mTOR pathways in osteosarcoma (102). LncRNA CERS6-AS1 regulated the MDM2/p53 axis and modulated glucose metabolism and progression of HCC (103). LncRNA WAC-AS1 sponged miR-320d and regulated the expression of ARPP19, which promoted glucose uptake and lactate production in HCC (104). LncRNA NR2F1-AS1 affected hypoxia-mediated glycolysis and migratory ability of HCC cells via targeting miR-140 and HK2 (105). Depletion of lncRNA HOTAIR reduced glycolysis via inhibition of miR-130a-3p and upregulation of HIF1α in HCC cells under hypoxia (106).

LncRNA MALAT1 modulated MYBL2/mTOR pathway and caused glucose metabolism changes in prostate cancer (107). LncRNA MIR31HG heightened glycolysis and tumor malignant progression via regulating miR-361-3p and YY1 transcription factor in colorectal cancer (108). LncRNA KCNQ1OT1 accelerated colorectal oncogenesis via promoting aerobic glycolysis by upregulation of HK2 (109). HNF1A-AS1 governed glycolysis, invasion and migration through targeting miR-124 and MYO6 in colorectal cancer (109). Similarly, LINC00265 enhanced glycolysis and lactate release via binding with miR-216b-5p and elevating the expression of TRIM44 in colorectal cancer (111). LncRNA RNUCR2 promoted glycolysis and EMT and proliferation of melanoma cells via interacting with miR-495-3p and upregulating HK2 in melanoma (112). LINC00242 combined miR-1-3p and elevated the expression of Glc6PD, leading to enhancement of aerobic glycolysis and oncogenesis of gastric cancer (113). LncRNA MSC-AS1 increased glycolysis and cell growth via targeting PFKFB3 expression in gastric cancer cells (114). OIP5-AS1 heightened aerobic glycolysis and proliferation via miR-186 sponge in gastric cancer (115).

LINC00551 inhibited glycolysis and blocked tumor progression via modulation of c-Myc-induced PKM2 expression in lung cancer (116). LncRNA CRYBG3 potentiated glycolysis via interaction with lactate dehydrogenase A (LDHA) in lung cancer (117). LncRNA DUXAP8 accelerated glycolysis, viability and migratory capacities via suppression of miR-409-3p and upregulation of HK2 and LDHA in NSCLC cells (118). LncRNA BCYRN1 accelerated glycolysis via controlling the miR-149 expression and elevating PKM2 expression in NSCLC (119). HOTTIP enhanced hypoxia-mediated glycolysis via modulation of miR-615-3p and HMGB3 in NSCLC cells (120). LINC00857 was found to regulate glycolysis and tumor progression via governing the Hippo signaling pathway by binding to miR-486-5p in ovarian cancer (121). Downregulation of LncRNA UCA1 attenuated glycolysis pathway and led to suppression of growth of pituitary cancer cells (122). Overexpression of LncRNA PCED1B-AS1 resulted in upregulation of glucose uptake, proliferation and lactate production in glioblastoma by activation of HIF-1α pathway (123). LncRNA HNF4A-AS1 elevated aerobic glycolysis and tumor progression via modulating hnRNPU/CTCF axis in neuroblastoma (124).

High/low glucose regulates IncRNAs in cancer

Some studies have demonstrated that high glucose or glucose deprivation affected the expression of IncRNAs in cancer cells. For example, U87 and LN18 glioma cells after glucose deprivation had upregulation of LncRNA TP53TG1 and glucose metabolism-associated genes, including LDHA, IDH1 and GRP79 (125). Downregulation of TP53TG1 suppressed proliferation and migration of U87 cells after glucose deprivation, while overexpression of TP53TG1 displayed the opposite functions (125). Low glucose condition promoted the efficacy of TP53TG1 compared with high glucose condition. This study suggested that glucose metabolism dysregulation can affect the expression of TP53TG1 and tumor proliferation and migration in glioma (125).

High glucose increased the expression of miR-483-3p in hepatocellular carcinoma (HCC) cells. Moreover, upregulation of miR-483-3p inhibited the expression of ER protein 29 (Erp29), resulting in promotion of proliferation and migration of HCC cells (126). Furthermore, LncRNA MEG3 can bind with miR-483-3p in HCC cells. High glucose also reduced the expression of LncRNA MEG3 in HCC cells. Consistently, silencing of LncRNA MEG3 suppressed the expression of Erp29 in HCC cells (126). This study showed that high glucose could affect the expression of LncRNA MEG3 and govern the miR-483-3p/Erp29 proteins in HCC patients, suggesting that management of LncRNA MEG3 could be promising for the treatment of HCC patients with diabetes (126). Low glucose elevated the expression of LncRNA HOXC-AS3, leading to promotion of metabolic reprogramming of breast cancer via binding to SIRT6 and inactivating HIF1α (127).

Targeting IncRNAs for treating DKD and cancer

Klotho is often known as an antiaging protein to prevent aging. Klotho has been identified to protect renal tubular EMT during the DKD development (52). Overexpression of Klotho reduced the LncRNA NEAT1 expression in HFD/STZ-mediated DKD mice. Moreover, overexpression of Klotho attenuated the expression levels of NEAT1 in BSA-treated HK2 cells (52). On the contrary, knockdown of Klotho increased the expression of LncRNA NEAT1 in HK2 cells. Thereby, knockdown of Klotho caused upregulation of NEAT1 and activation of EMT and fibrosis in a ERK1/2-dependent manner (52). Another study
showed that Klotho blocked EMT via downregulation of early growth response factor 1 (Egr-1) by suppression of the ERK1/2 pathway in DKD mice (128). Similarly, Klotho decreased Egr-1 expression via repressing TGF-β1/Smad3 pathway in human mesangial cells after high glucose exposures (129). Triptolide, a diterpenoid epoxide that is obtained from the thunder god vine, blocked renal tubular EMT via modulation of miR-188-5p-involved PI3K/Akt pathway in DKD (130). Several studies have showed that triptolide regulated the expression of multiple lncRNAs, including lncRNAs WAKMAR2, PACER, ENST00000619282, RP11-83J16.1 (131–135). Therefore, whether triptolide regulates the lncRNA expression in DKD needs to be further explored. Berberine, an isoquinoline alkaloid, has been reported to upregulate the expression of lncRNA GASS to reduce the mitochondrial ROS generation in HK-2 cells under high glucose environment through regulation of miR-18a-5p and C/EBPβ expression (136). The antisense oligonucleotide treatment by targeting specific lncRNAs could provide targeted medicine to cure DKD and cancer in the future.

**Conclusion**

In summary, burgeoning data demonstrate that lncRNAs play an essential role in the development of DKD and diabetes-associated cancer. LncRNAs could be diagnosis and prognosis biomarkers for DKD and diabetes-related cancer. Modulation of lncRNAs might be a promising strategy for treating DKD and diabetes-associated cancer. It is important to note that it is far from being fully clarified, although some studies have explored the role of lncRNAs in DKD and cancer patients with DM. A small number of lncRNAs are identified in regulation of DKD and cancer patients with abnormal glucose metabolism. Whether other lncRNAs also participate in DKD and diabetes-associated cancer need to be explored. Compared with other factors such as m6A and signaling pathways, it remains questionable whether lncRNAs are more important in modulation of DKD and diabetes-related cancers. Addressing these questions will help us understand the mechanism of lncRNAs-regulated DKD and cancers, which could provide the clues for discovering new therapeutic strategy for DKD and cancer patients with diabetes.

**Author contributions**

YC and XW wrote the manuscript. YX made the figures. YC and PW edited the manuscript and supervised this study. All authors read and approved the final manuscript.

**Funding**

This work was supported by National Natural Science Foundation of China (82260876) and Hainan Province Science and Technology Special Fund (ZDKJ2021034).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**References**

1. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. *Nat Rev Drug Discov* (2021) 20(8):629–51. doi: 10.1038/s41573-021-00427-8

2. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. *Nat Rev Mol Cell Biol* (2021) 22(2):96–118. doi: 10.1038/s41580-020-00315-9

3. Zhang P, Wu W, Chen Q, Chen M. Non-coding RNAs and their integrated networks. *J Integr Bioinform* (2019) 16(3):20190027. doi: 10.1515/jib-2019-0027

4. Andergassen D, Rinn JL. From genotype to phenotype: Genetics of mammalian long non-coding RNAs in vivo. *Nat Rev Genet* (2022) 23(4):229–43. doi: 10.1038/s41576-021-00427-8

5. Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y, et al. Long non-coding RNAs: The regulatory mechanisms, research strategies, and future directions in cancers. *Front Oncol* (2020) 10:598817. doi: 10.3389/fonc.2020.598817

6. Xie W, Chu M, Song G, Zuo Z, Han Z, Chen C, et al. Emerging roles of long non-coding RNAs in chemoresistance of pancreatic cancer. *Semin Cancer Biol* (2022) 83:303–18. doi: 10.1016/j.semcancer.2020.11.004

7. Jiang W, Xia J, Xie S, Zou R, Pan S, Wang ZW, et al. Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. *Drug Resist Update* (2020) 50:100683. doi: 10.1016/j.drup.2020.100683

8. Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long noncoding RNAs in cancer metastasis. *Nat Rev Cancer* (2021) 21(7):446–60. doi: 10.1038/s41568-021-00353-1
Dysregulated expression but redundant function of the long non-coding RNA facilitates high glucose-induced mesangial cell proliferation, and diabetic kidney disease.

Methods among microRNAs, long non-coding RNAs, and messenger RNAs to understand medicine in diabetic kidney disease?

The neuroinflammation regulators in neurodegenerative diseases.

miR-2355-3p/IL6ST axis.

miR-147a/WNT2B axis.

miR-15b-5p/TLR4 signaling axis.

miR-142-5p axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-147a/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.

miR-142-5p/WNT2B axis.
cells in diabetic kidney disease through the ERK1/2 signaling pathway. *Exp Mol Med* (2020) 52(11):e1039. doi: 10.1038/s12276-020-00041-3

53. Li C, Liu YF, Huang C, Chen XY, Xu CY, Chen Y. Long non-coding RNA NEAT1 sponges miR-129 to modulate renal fibrosis by regulation of collagen type I. *Am J Physiol Renal Physiol* (2020) 319(1):F93–F105. doi: 10.1152/ajprenal.00552.2019

54. Huang S, Xu Y, Ge X, Xu B, Peng W, Jiang X, et al. Long non-coding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway. *J Cell Physiol* (2019) 234(7):11200–7. doi: 10.1002/jcp.27770

55. Wang X, Xu Y, Zhu YC, Wang YK, Li J, Li XY, et al. LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting miR-27b-3p and ZEB1 in diabetic nephropathy. *J Cell Physiol* (2019) 234(8):12926–33. doi: 10.1002/jcp.27599

56. Ma J, Zhao N, Du L, Wang Y. Downregulation of LncRNA NEAT1 inhibits mesangial cell proliferation, fibrosis, and inflammation but promotes apoptosis in diabetic nephropathy. *Int J Clin Exp Pathol* (2019) 12(4):1174–83. doi: 10.2147/IJCEP.S159146

57. Li N, Jia T, Li YR. LncRNA NEAT1 accelerates the occurrence and development of diabetic nephropathy by sponging miR-23c. *Eur Rev Med Pharmacol Sci* (2020) 24(3):1325–37. doi: 10.26355/eurrev_202002_20190

58. Zhan JF, Huang HW, Huang C, Hu LL, Xu WW. Long non-coding RNA NEAT1 promotes pyroptosis in diabetic nephropathy via mediating the miR-34c–NLRP3 axis. *Kidney Blood Press Res* (2020) 45(4):589–602. doi: 10.1159/000508083

59. Luo L, Chen J, Zhang C, Guo Y, Liu W, Liu W, et al. LncRNA NEAT1 promotes high glucose-induced mesangial cell hypertrophy by targeting miR-222-3p/CDKN1B axis. *J Biol Chem* (2021) 296(47):15840–52. doi: 10.1074/jbc.RA120.013228

60. Long J, Badal SS, Ye Z, Wang Y, Ayanga BA, Galvan DL, et al. Long non-coding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy. *J Clin Invest* (2016) 126(11):4205–18. doi: 10.1172/JCI87927

61. Li SY, Suastik K. The long non-coding RNA Tug3 connects metabolic changes with kidney disease in podocytes. *J Clin Invest* (2016) 126(11):4072–5. doi: 10.1172/JCI89028

62. Zhang B, Zhao C, Hou L, Wu Y. Silencing of the IncRNA TUG1 attenuates the epithelial-mesenchymal transition of renal tubular epithelial cells by sponging miR-141-3p via regulating beta-catenin. *Am J Physiol Renal Physiol* (2020) 319(6):F1125–34. doi: 10.1152/ajprenal.00322.2020

63. Duan LJ, Ding M, Heo JI, Cui YT, Li CI, Yu DM. Long non-coding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARgamma in diabetic nephropathy. *Biochem Biophys Res Commun* (2017) 484(3):598–604. doi: 10.1016/j.bbrc.2017.01.145

64. Lei M, Ke G, Wang Y, Luo D, Hu Y. Long non-coding RNA TUG1 sponges microRNA-9-3p to protect podocytes from high glucose-induced apoptosis and mitochondrial dysfunction via SIRT1 upregulation. *Exp Ther Med* (2022) 23(3):236. doi: 10.3892/etm.2022.11161

65. Lei X, Zhang L, Li Z, Ren J. Astaxanthin IV/lnRNA-TUG1/TRA5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. Drug Des Devel Ther (2018) 12:2875–93. doi: 10.2147/DDDT.S166525

66. Shen H, Ming Y, Xu C, Xu Y, Zhao S, Zhang Q. Deregulation of long noncoding RNA TUG1 contributes to excessive podocytes apoptosis by activating endoplasmic reticulum stress in the development of diabetic nephropathy. *J Cell Physiol* (2019) 234(9):15123–33. doi: 10.1002/jcp.28153

67. Zang XL, Liu J, Zang ZH, Wang Y, Mei CL. LncRNA TUG1 inhibits the proliferation and fibrosis of mesangial cells in diabetic nephropathy via inhibiting the PI3K/AKT signaling pathway. *Eur Rev Med Pharmacol Sci* (2019) 23(17):7519–25. doi: 10.26355/eurrev_201909_22855

68. Wang F, Gao X, Zhang R, Zhao P, Sun Y, Li C. LncRNA TUG1 ameliorates diabetic nephropathy by inhibiting miR-21 to promote TIMP3-expression. *Int J Clin Exp Pathol* (2019) 12(3):717–29.

69. Meng D, Wu L, Li Z, Ma X, Zhao S, Zhao D, et al. LncRNA TUG1 ameliorates diabetic nephropathy via inhibition of PUMA/PTEN signaling pathway. *J Leuko Biol* (2021) 111(3):553–62. doi: 10.1007/s00292-020-04998-6

70. Yang Y, Liu S, Wang X, Sun LL, et al. Analysis of circulating lncRNA as a novel serum biomarker of diabetic nephropathy in patients with type 2 diabetes. *Med Sci Monit* (2018) 24:6079–84. doi: 10.12659/MSM.909510

71. Yang Y, Lu Q, Fan Q, Wang X, Lu X, et al. Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy. Differential expression profile of circulating lncRNA. *Clin Nephrol* (2019) 92(1):25–35. doi: 10.5451/cnin2019092

72. Zhang XL, Zhu HQ, Zhang Y, Zhang CY, Jiao JS, Xing XY. LncRNA CASC2 regulates high glucose-induced proliferation, extracellular matrix accumulation and oxidative stress of renal tubular epithelial cells via miR-138-3p/FOXM1 axis. *Eur Rev Med Pharmacol Sci* (2020) 24(2):802–12. doi: 10.26355/eurrev_202001_20863
RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells through mediating miR-135a-5p/TIMP3 axis and JNK signaling. Cheng et al. 10.3389/fonc.2022.1035487 Mol Med.

Overexpressed in triple-negative breast cancer and predicts chemoresistance and tumor recurrence.

miR-876-5p/HKDC1 axis regulates endometrial cancer progression in a high epigenetic mechanisms.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.

miR-615-3p/BCYRN1 promotes glycolysis and tumor progression by regulating the miR149/PKM2 axis in nonsmall cell lung cancer. Mol Med Rep (2020) 21(3):1509-16. doi: 10.3892/mmr.2020.10944.
134. Zhou X, Xie D, Huang J, Lu A, Wang R, Lin Y, et al. Therapeutic effects of (5R)-5-Hydroxytriptolide on fibroblast-like synoviocytes in rheumatoid arthritis via IncRNA WAKMAR2/miR-4478/E2F1/p53 axis. *Front Immunol* (2021) 12:605616. doi:10.3389/fimmu.2021.605616

135. Xiong S, Li Y, Xiang Y, Peng N, Shen C, Cai Y, et al. Dysregulation of IncRNA and circRNA expression in mouse testes after exposure to triptolide. *Curr Drug Metab* (2019) 20(8):665–73. doi: 10.2174/1389200220666190729130020

136. Xu J, Liu L, Gan L, Hu Y, Xiang P, Xing Y, et al. Berberine acts on C/EBPbeta/IncRNA Gas5/miR-18a-5p loop to decrease the mitochondrial ROS generation in HK-2 cells. *Front Endocrinol (Lausanne)* (2021) 12:675834. doi: 10.3389/fendo.2021.675834